25/10/2010
Afghanistan
New bivalent polio vaccine playing key role in global polio eradication
Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial
A head to head trial against current poliovirus vaccines has found that the new bivalent oral vaccine against poliovirus, which targets both the remaining types of poliovirus concurrently, induces a stronger immune response than the traditional trivalent vaccine and a similar immune response to the latest monovalent (monovalent type 1 or monovalent type 3) vaccines. Furthermore, it is easier to administer, allowing children to be immunised against the two remaining types of wild poliovirus in a single oral dose. These are the conclusions of an Article published Online First in The Lancet.
For details, please go to:
http://www.thelancet.com
Related News
19/10/2021
For a few incredible eradicators, a life’s purpose doesn’t stop at retirement
19/10/2021
Update on polio eradication efforts in Pakistan for September 2021
18/10/2021
WHO and UNICEF welcome the decision by the Taliban leadership supporting the resumption of house-to-house polio vaccination across Afghanistan.
13/10/2021
Virus isolated from Rivne province in north-west of country
10/10/2021
The recommendation further advances nOPV2 as a critical new tool in the fight against circulating vaccine-derived poliovirus type 2 (cVDPV2)
29/09/2021
More often than not, the road to a meaningful triumph is a bumpy one.